Mirum Pharmaceuticals, Inc.
Foster City, California, United States · Healthcare, Pharmaceutical Manufacturing
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, Cholbam® (cholic acid) capsules, and Chenodal® (chenodiol) tablets.
Key facts
- Headquarters
- Foster City, California, United States
- Employees
- Unknown
- Industries
- Healthcare, Pharmaceutical Manufacturing
- Status
- Public (MIRM)
- Website
- mirumpharma.com
- Company page
Recent activity at Mirum Pharmaceuticals, Inc.
- : Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer
- : SEC 8-K (8.01): On November 10, 2026, Mirum Pharmaceuticals, Inc. announced that the primary endpoint was met in the Phase 3 AZURE-4 study evaluating brelovitug for treating chronic hepatitis delta virus (HDV). This study enrolled 113 treatment-naïve patients, highlighting the efficacy of brelovitug, with 59% of patients receiving 300 mg once weekly achieving the combined endpoint of virologic response and ALT normalization at Week 24. The announcement included significant data presented at the American Association for the Study of Liver Diseases, showcasing improvements in viral suppression and liver health in patients, particularly those with advanced cirrhosis. The results will form part of the company's U.S. registration package for brelovitug, indicating a substantial step forward in the development of this treatment.
- : SEC 8-K (8.01): On October 26, 2026, Mirum Pharmaceuticals, Inc. announced positive results from Cohort 2 of the pivotal PROGRESS study of ATEBRIOZ (zilurgisertib) in pediatric patients aged 6 to <12 years with fibrodysplasia ossificans progressiva (FOP). The study demonstrated that at Week 24, patients receiving zilurgisertib showed a significant reduction in total heterotopic ossification lesion volume by 8.09 cm³ compared to an increase of 9.14 cm³ in the placebo group (p=0.003). Furthermore, no new HO lesions developed in the zilurgisertib-treated group. These results support the company's plan for a supplemental New Drug Application submission in the first half of 2027 to expand ATEBRIOZ’s indication to younger pediatric patients. This progress reflects positive momentum towards potential new treatment options for this challenging condition.
- : SEC 8-K (8.01): On October 12, 2026, Mirum Pharmaceuticals, Inc. announced topline results from the Phase 3 EXPAND study, which evaluated LIVMARLI (maralixibat) for cholestatic pruritus in patients with ultra-rare cholestatic liver diseases, particularly biliary atresia. The study met its primary endpoint with a statistically significant improvement in pruritus as measured by a 1.81-point decrease in severity scores for pediatric patients treated with maralixibat compared to placebo. Additionally, there was a notable 70.1% reduction in serum bile acids with maralixibat, while no new safety signals were identified. The company plans to submit a supplemental New Drug Application in the first half of 2027 based on these promising results.
- : SEC 8-K (8.01): On September 25, 2026, Mirum Pharmaceuticals, Inc. announced FDA approval for Atebrioz™ (zilurgisertib) tablets, which are designed to reduce total new heterotopic ossification in patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dosing for Atebrioz is 100 mg administered orally once daily. This drug was developed by Incyte Corporation, which licensed it to Mirum for worldwide development and commercialization, indicating a significant advancement in treatment options for a rare condition. This approval highlights the strategic collaboration between Mirum and Incyte, expanding Mirum's product offerings and potential market reach.
- : SEC 8-K (5.02): On September 8, 2026, Mirum Pharmaceuticals, Inc. announced the appointment of Rob Myers, M.D., as the new Chief Medical Officer, effective September 21, 2026. This change follows the departure of Joanne Quan, M.D., who ceased her role as Chief Medical Officer on September 2, 2026, with her termination expected on October 19, 2026. In connection with Dr. Quan's exit, the company plans to enter into a Separation Agreement, providing her with severance benefits per the Severance Plan, along with an extension for her stock options and a payment of her 2026 annual target bonus, contingent on fulfilling specific conditions. The transition signifies a strategic shift in the leadership of the medical team as the company prepares for ongoing and future operations.
- : SEC 8-K (1.01): On May 15, 2026, Mirum Pharmaceuticals, Inc. entered into a material definitive agreement by issuing $690.0 million of its 0.00% Convertible Senior Notes due 2032. This issuance included the full exercise of an option by initial purchasers for an additional $90.0 million in Notes. The Notes are governed by an indenture with U.S. Bank Trust Company, where they stand as senior, unsecured obligations. Notably, the Notes lack regular interest and cannot be redeemed before specific conditions are met, whereas noteholders can convert their holdings under certain conditions related to the company's stock performance and corporate actions. This strategic move is expected to impact the company's capital structure significantly and aligns with their long-term financing objectives.
- : SEC 8-K (8.01): On May 4, 2026, Mirum Pharmaceuticals, Inc. disclosed that the primary endpoint was successfully met in its VISTAS Phase 2b clinical study of volixibat, an investigative drug for treating primary sclerosing cholangitis (PSC). The study involved 158 patients treated with either volixibat or a placebo, demonstrating a significant 2.72 point improvement in itch severity as per the Adult Itch Reported Outcome scale. The results indicate that volixibat could potentially be the first effective treatment for cholestatic pruritus associated with PSC. Furthermore, the company has scheduled a pre-New Drug Application meeting with the FDA in summer 2026, with an NDA submission anticipated later that year.
- : SEC 8-K (8.01): On April 27, 2026, Mirum Pharmaceuticals, Inc. announced favorable results from the Phase 2b portion of the AZURE-1 study evaluating brelovitug, an investigational treatment for chronic hepatitis delta virus (HDV). The study involved 53 patients, where 100% of those receiving a 300 mg weekly dosage and 75% of those on 900 mg every four weeks showed significant virologic response, a stark contrast to 0% in the delayed treatment group. These results highlight brelovitug's potential as a viable single-agent therapy against HDV and will be discussed further at the upcoming EASL Congress in May 2026. With Phase 3 studies projected to yield topline data in H2 2026, Mirum anticipates a potential BLA submission and U.S. commercial launch in 2027, which indicates significant strategic implications for the company's portfolio in antiviral therapy.
- : SEC 8-K (2.01): On January 23, 2026, Mirum Pharmaceuticals, Inc. completed the acquisition of Bluejay Therapeutics, Inc. per a previously announced Merger Agreement dated December 6, 2025. This involved two mergers: the first where Bjork Merger Sub I, Inc. merged with Bluejay, making it a wholly owned subsidiary, and the second where Bluejay merged with Bjork Merger Sub II, LLC. Mirum acquired approximately $56.6 million in net cash and will disburse up to $280.8 million in cash and 4,673,597 shares of common stock as Upfront Consideration. Additionally, up to $25.8 million in cash and 522,375 shares will be paid as Holdback Consideration, with potential milestone payments of up to $200 million based on certain net sales achievements. These transactions significantly expand Mirum's portfolio and strategic capabilities in the biopharmaceutical sector.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Mirum Pharmaceuticals, Inc. funding history
| Date | Round | Amount |
|---|---|---|
| Dec 2025 | Post-IPO Equity | $68.5M |
| Dec 2020 | Venture | $10.0M |
| Nov 2018 | Venture | $60.1M |
Leadership
- Chris Peetz, Director
- Tiba Aynechi, Director
- Jonathan Leff, Director
- Patrick Heron, Director
- Ed Mathers, Director
- Michael Grey, Executive Officer, Director
- Rob Myers, Chief Medical Officer
- Doug Sheehy, Chief Legal Officer
- Peter Radovich, Chief Operating Officer
- Joanne Quan, Chief Medical Officer
- Eric Bjerkholt
- Susan Dube, Executive Officer
Verified email and direct lines for Mirum Pharmaceuticals, Inc.’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Companies similar to Mirum Pharmaceuticals, Inc.
- Bridge Therapeutics · Healthcare, Pharmaceutical Manufacturing
- Tris Pharma · Healthcare, Pharmaceutical Manufacturing
- Elligo Health Research, Inc. · Healthcare, Pharmaceutical Manufacturing
- Zurex Pharma · Healthcare, Pharmaceutical Manufacturing
- Panbela Therapeutics · Healthcare, Pharmaceutical Manufacturing
About Mirum Pharmaceuticals, Inc.: questions and answers
What does Mirum Pharmaceuticals, Inc. do?
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, Cholbam® (cholic acid) capsules, and Chenodal® (chenodiol) tablets.
Where is Mirum Pharmaceuticals, Inc. headquartered?
Mirum Pharmaceuticals, Inc. is headquartered in Foster City, California, United States.
Has Mirum Pharmaceuticals, Inc. raised funding?
Yes. Fundz has recorded 3 funding events for Mirum Pharmaceuticals, Inc.. The most recent, Post-IPO Equity of $68.5M, was in Dec 2025.
What is the latest news on Mirum Pharmaceuticals, Inc.?
On Sep 8, 2026, Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer
Is Mirum Pharmaceuticals, Inc. a public company?
Yes. Mirum Pharmaceuticals, Inc. is publicly traded under the ticker MIRM.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy